FDA Clears 'Recharge-Free' Neurostimulation Device for Chronic Pain

Megan Brooks

Disclosures

September 27, 2019

The US Food and Drug Administration (FDA) has approved Abbott Laboratories' Proclaim XR neurostimulation system for chronic pain patients. The device has a battery life of up to 10 years, the company announced.

The Proclaim XR platform uses the company's proprietary low energy BurstDR stimulation waveform coupled with a low dosing protocol to provide effective pain relief with lower doses of stimulation, which significantly extends the system's battery life.

"Abbott's low-dose and low-energy pain management technology is designed to provide pain relief and improve system longevity, offering patients a life-altering option for pain relief without the hassles of recharging," the company said in a news release.

Alternative neurostimulation systems may use higher frequencies or multiple waveforms that use more energy, requiring them to be recharged daily. The Proclaim XR system allows physicians to identify the lowest effective dose of BurstDR stimulation customized to each patient, optimizing the longevity of the system while maintaining effective pain relief, Abbott said.

The Proclaim XR system was developed based on positive results from the BOLD study in which all 24 enrolled patients on a low-energy BurstDR dosing program saw pain relief with < 6 hours of battery use per day. About half of those patients achieved pain relief with the lowest effective dose (< 2 hours of daily battery use).

"For the 50 million people living with chronic pain in the United States this is a new and exciting treatment that is supported with evidence validated by the BOLD study, an established protocol for titrated intermittent dosing to give patients individualized pain relief while using therapy for 6 hours or less per day," Timothy Deer, MD, president and CEO of The Spine and Nerve Center of the Virginias in Charleston, West Virginia, said in the release.

"Proclaim XR is a major advancement in spinal cord stimulation, and is an evidence-based therapy that is mobile app-based and features upgradeable software. This means patients won't need surgery to benefit from future advances in this technology," said Deer.

"Having access to reliable pain relief — from a system that doesn't have the hassle of needing to be recharged — is a game changer in helping people live their best lives, free from pain," Jacqueline Weisbein, DO, Napa Valley Orthopaedic Medical Group in Napa, California, commented in the release.

For more Medscape Neurology news, join us on Facebook and Twitter.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....